136 related articles for article (PubMed ID: 16968871)
1. Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer.
Gusella M; Crepaldi G; Barile C; Bononi A; Menon D; Toso S; Scapoli D; Stievano L; Ferrazzi E; Grigoletto F; Ferrari M; Padrini R
Ann Oncol; 2006 Nov; 17(11):1656-60. PubMed ID: 16968871
[TBL] [Abstract][Full Text] [Related]
2. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Di Paolo A; Danesi R; Falcone A; Cionini L; Vannozzi F; Masi G; Allegrini G; Mini E; Bocci G; Conte PF; Del Tacca M
Ann Oncol; 2001 Sep; 12(9):1301-6. PubMed ID: 11697844
[TBL] [Abstract][Full Text] [Related]
3. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
[TBL] [Abstract][Full Text] [Related]
4. A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity.
Esin E; Telli TA; Yuce D; Yalcin S
Tumori; 2018 Jun; 104(3):157-164. PubMed ID: 28708227
[TBL] [Abstract][Full Text] [Related]
5. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Gamelin E; Boisdron-Celle M; Guérin-Meyer V; Delva R; Lortholary A; Genevieve F; Larra F; Ifrah N; Robert J
J Clin Oncol; 1999 Apr; 17(4):1105. PubMed ID: 10561167
[TBL] [Abstract][Full Text] [Related]
6. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Gamelin E; Delva R; Jacob J; Merrouche Y; Raoul JL; Pezet D; Dorval E; Piot G; Morel A; Boisdron-Celle M
J Clin Oncol; 2008 May; 26(13):2099-105. PubMed ID: 18445839
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
Woloch C; Di Paolo A; Marouani H; Bocci G; Ciccolini J; Lacarelle B; Danesi R; Iliadis A
Curr Top Med Chem; 2012; 12(15):1713-9. PubMed ID: 22978343
[TBL] [Abstract][Full Text] [Related]
9. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
[TBL] [Abstract][Full Text] [Related]
10. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
11. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
12. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion.
Grem JL; Quinn M; Ismail AS; Takimoto CH; Lush R; Liewehr DJ; Steinberg SM; Balis FM; Chen AP; Monahan BP; Harold N; Corse W; Pang J; Murphy RF; Allegra CJ; Hamilton JM
Cancer Chemother Pharmacol; 2001; 47(2):117-25. PubMed ID: 11269737
[TBL] [Abstract][Full Text] [Related]
14. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
[TBL] [Abstract][Full Text] [Related]
15. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell AB; Conte PF
J Clin Oncol; 1996 Mar; 14(3):729-36. PubMed ID: 8622018
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity.
Codacci-Pisanelli G; Pinedo HM; Lankelma J; Van Groeningen CJ; Van Kuilenburg AB; Van Gennip AH; Peters GJ
J Chemother; 2005 Jun; 17(3):315-20. PubMed ID: 16038526
[TBL] [Abstract][Full Text] [Related]
18. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
[TBL] [Abstract][Full Text] [Related]
19. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
[TBL] [Abstract][Full Text] [Related]
20. Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients.
Fang L; Jiang Y; Yang Y; Zheng Y; Zheng J; Jiang H; Zhang S; Lin L; Zheng J; Zhang S; Zhuang X
Oncotarget; 2016 Dec; 7(49):81880-81887. PubMed ID: 27636992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
